Guardant Health Raises Over $600 Million in Public Offering of Common Stock

Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, is pleased to announce the successful pricing of a highly anticipated underwritten public offering of 12,500,000 shares of its common stock. The offering, priced at a public offering price of $28.00 per share, is expected to provide the company with a gross proceeds of up to $350.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.

The offering is expected to close on or about May 25, 2023, pending customary closing conditions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen and SVB Securities are collaborating to lead the offering, acting as the joint book-running managers. By coming together as one, these financial powerhouses seek to facilitate an exciting investment opportunity for potential investors.

Guardant Health is offering a unique opportunity to invest in their shares of common stock, through an automatic shelf registration statement filed with the US Securities and Exchange Commission, providing an immediate effect. This is an exciting chance to support an innovative biotech company and benefit from their success.

To learn more about our upcoming IPO, you can obtain copies of the preliminary prospectus supplement and accompanying prospectus by getting in touch with us. Discover more about our future plans and be a part of this exciting opportunity today!

Investors, seize your chance to own a stake in this innovative venture! Interested parties can take advantage of this incredible opportunity, joining the movement in an effort to help shape the success of the company. However, this offer isn’t available in every state, as any sale of these securities must first comply with all applicable securities laws in each respective jurisdiction. So don’t wait; make your move now and join us in this monumental endeavor!

About Guardant Health

At Guardant Health, we are devoted to unlocking the secrets of cancer with superhuman precision and power. We are driven to pave the way for a world without cancer, using state-of-the-art cancer testing solutions such as Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, GuardantINFINITY™, and Guardant Reveal™, alongside advanced data analytics. Our revolutionary tests help reduce the cost of cancer care while increasing better patient outcomes. This is further extended through our cancer screening portfolio, Shield™ which ensures early detection and prevention of cancer. Together, we can join forces to conquer cancer worldwide.

Forward Looking Statements

Guardant Health is excited to announce the upcoming closing of its public offering. This offering presents a unique opportunity to be a part of a rapidly growing, cutting-edge company. Despite the current risks and uncertainties associated with investing in shares of a public company, such as market interest rates, the trading price and volatility of Guardant Health’s common stock, and risks associated with its business, investors have the ability to make a long-term investment that could reap significant rewards. Guardant Health is dedicated to its investors and will remain committed to providing periodic updates regarding its progress.

Leave a Comment